Vaxxinity, Inc. announced it will present clinical data from its UB-312 program in Parkinson's disease and preclinical data from its anti-tau program in Alzheimer's disease at the International Conference on Alzheimer's and Parkinson's Diseases and related neurological disorders (AD/PD 2024), taking place March 5-9, 2024 virtually and in Lisbon, Portugal. Presentation details are as follows: Oral Presentation Title: Evidence of Target Engagement in a Phase 1 Clinical Trial of UB-312 in Parkinson's Disease Presenter: Jean-Cosme Dodart, Ph.D., SVP of Research at Vaxxinity Location: Auditorium VIII Date & Time: March 6, 2024 at 6:00 PM WET Poster Presentation Title: A Randomized, Double Blind, Placebo-Controlled Study with UB-312, an Anti-Alpha-Synuclein Peptide Vaccine in Parkinson's Disease Patients Poster Number: P1049 /#720 Authors: Pepijn Eijsvogel, Hui Jing Yu, Philip Kremer, Lauren Fedor, Igor Radanovic, Dario Mirski, Maurits Vissers, Marieke De Kam, Jean-Cosme Dodart., Geert Jan Groeneveld, Poster Presentation Title: Efficacy of a New Vaccine Targeting Tau in Mouse Models. Poster Number: P0770 /#1617 Authors: Christopher Brown, Louise Kelly, Jeanne Brooks, Matthew Longo, Justin Boyd, Roxana Carare, Jean-Cosme Dodart.